REGN Stock Analysis: Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). O
- Latest close
- $758.27
- 20-day change
- -7.96%
- Trend state
- LEAN BEAR
- Classification
- Healthcare · Biotechnology
Market context
Regeneron Pharmaceuticals Inc moved -7.96% over the latest 20-session window. BullRecon currently classifies the broader setup as LEAN BEAR.
Latest report
The latest cached company filing period (FY2025 · $14.3B revenue · $4.5B net income) is used alongside annual and quarterly history. Values remain tied to their reported period.
Six-dimension read
Profitability is currently the strongest dimension at 5.7/6, while Future is the lowest at 3.4/6. Scores are comparative research signals, not forecasts.